DENTSPLY SIRONA Inc. Faces Class Action Lawsuit
Pomerantz LLP has launched a class action lawsuit against DENTSPLY SIRONA Inc. (NASDAQ: XRAY), prompting shareholders who have incurred losses to contact the firm. This legal action highlights concerns regarding potential securities fraud and other questionable business practices linked to the company's recent activities.
Important Deadlines for Shareholders
If you purchased or acquired DENTSPLY securities during the specified class period, it's crucial to know that you have until January 27, 2025, to request the court to appoint you as Lead Plaintiff. Interested shareholders are encouraged to provide their mailing address, phone number, and the number of shares they purchased for more information.
The Allegations
The core of the lawsuit revolves around claims that DENTSPLY SIRONA and select executives may have engaged in deceptive practices that misled investors. These actions may have resulted in significant financial losses for shareholders.
Recent Developments Impacting DENTSPLY SIRONA
In a notable transaction, DENTSPLY SIRONA spent $1.04 billion to acquire Byte, a firm that specializes in developing clear dental aligners, back in December 2020. However, on October 24, 2024, the company announced a voluntary halt to the sales and marketing of Byte Aligners and Impression Kits. This decision was made as the company undertook a review of regulatory requirements related to these products. DENTSPLY described this action as a precautionary measure while revealing an anticipated impairment of goodwill between $450 million and $550 million.
Stock Price Reaction
This announcement negatively impacted DENTSPLY's stock, causing a decline of over 4%, as it closed at $23.31 per share on October 25, 2024. Investors were troubled as the company also revised its earnings outlook amidst these developments.
Further Financial Disclosures
Following these events, DENTSPLY issued its third-quarter financial results on November 7, 2024, reporting a non-cash charge of $495 million linked to goodwill impairment. The revised expectations detailed a notable drop in organic sales outlook, which spurred further panic in the market.
Impact on Stock Value
As a direct consequence of these disclosures, DENTSPLY's stock price plummeted by approximately 28%, closing at just $17.26 per share on the same day. Investors were left with concerns regarding the future of the company's orthodontic ventures.
About Pomerantz LLP
Pomerantz LLP is recognized as one of the leading firms in corporate securities class actions, with a legacy dating back over 85 years. The firm has a reputable track record in advocating for victims of securities fraud and corporate misconduct, recovering significant damages for class members.
Frequently Asked Questions
What is the class action lawsuit against DENTSPLY SIRONA about?
The lawsuit pertains to allegations of securities fraud and unlawful business practices by DENTSPLY and its executives, affecting shareholder investments.
Who can participate in the class action?
Shareholders who purchased or acquired DENTSPLY securities during the class period can potentially be involved by requesting to be appointed as Lead Plaintiff.
What deadlines should shareholders be aware of?
Shareholders must act by January 27, 2025, to apply to be considered for the Lead Plaintiff position in the lawsuit against DENTSPLY SIRONA.
What recent actions by DENTSPLY contributed to the lawsuit?
The company’s suspension of sales for Byte products and the subsequent goodwill impairment announcement significantly impacted investor confidence and stock prices.
How can investors get more information about the lawsuit?
Investors seeking more information can contact Pomerantz LLP directly, providing their contact details and share information.
